Cellular and Molecular Life SciencesCell BiologyPeer-reviewed journal article
Molecular Control of Non-Muscle Myosin II-A Aggregation and Intracellular Dynamics by motor- or tail-specific MYH9 Mutations
Clara Llorente-GonzáleziD, Kamila R. MustafinaiD, Gloria Asensio-JuáreziD, Marina Garrido-CasadoiD, Vanessa C. TalayeroiD, Rafael Perez-Diaz, Hugo Ramos-SolanoiD, James R. SellersiD, Krishna ChinthalapudiiD, Paul W. WisemaniD, Sarah M. HeissleriD, Miguel Vicente‐ManzanaresiD
Abstract
Mutations in the MYH9 gene, which encodes the actin-based molecular motor non-muscle myosin II-A (NM2-A), cause a group of blood disorders termed MYH9-related diseases (MYH9-RD). While correlation between genotype and phenotype is not well characterized at a molecular level, motor mutations seem to cause more severe phenotypes than tail mutations. Motor domain mutation N93K, previously described as activity-impairing, causes in fact an almost non-significant defect on motor function in vitro. Conversely, it increases NM2-A filament stability and interaction with the myosin chaperone UNC45a in stress fiber-forming cells. This also alters its subcellular localization and effect on adhesion dynamics. Similar cellular effects are observed in cells expressing NM2-A E1841K, a prototypical tail mutation. In cells devoid of stress fibers such as megakaryocytes, NM2-A N93K forms large, amorphous, concentration-dependent aggregates that also contain wild type NM2-A and UNC45a. Conversely, NM2-A E1841K forms concentration-independent aggregates that exclude wild type NM2-A and UNC45a. Our data shows that the N93K mutation reduces the fraction of functional cellular NM2-A by enhancing the stability of NM2-A filaments and/or promoting protein aggregation together with wild type NM2-A. Conversely, NM2-A E1841K form aggregates that do not affect wild type NM2-A. These observations are consistent with the molecular severity observed in primary cells from patients of these genotypes.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- research focus: chromatin & epigenetic regulation
- approach: experimental assay
- Citations
- 1
- FWCI
- 4.90
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Disease-associated MYH11 tail variants disrupt vascular smooth muscle myosin II filament dynamics and cell mechanics
Sasha K. Demeulenaere, Margaret A. Bennett, … Jordan R. Beach·bioRxiv·Oct 23, 2026
- Reduced platelet forces underlie impaired hemostasis in mouse models of MYH9-related disease
J. Baumann, L. Sachs, … M. Bender·bioRxiv·Nov 10, 2021
- Impairments in contractility and cytoskeletal organisation cause nuclear defects in nemaline myopathy
J. A. Ross, Y. Levy, … J. Ochala·bioRxiv·Jan 28, 2019
- The membrane skeleton density of red blood cells in MYH9-related disease patients is decreased
Shaopeng Sun, Jiabin Pan, … Xiang‐dong Li·Bioscience ReportsPeer-reviewed·Sep 17, 2026
- Structural basis of nonmuscle myosin-2 autoinhibition mechanisms
Sarah M. Heissler, Giovanna Grandinetti, … Krishna Chinthalapudi·Nature CommunicationsPeer-reviewed·Jun 20, 2026
- Mechanoaccumulation of non-muscle myosin IIB during mitosis requires its translocation activity
C. Wang, J. Ding, … T. G. Chew·bioRxiv·Sep 8, 2021